ReviewRevista medica del Instituto Mexicano del Seguro Social2026
[Rh blood group: Review and importance of genotyping].
Review in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rh antigen is a transmembrane protein whose presence or absence is genetically inherited in humans. The genetic expression is controlled by 2 closely linked genes. The expression of the group (the antigen) can be modified by mutations or deletions in the gene that encodes it, leading to discrepancies that can sometimes only be resolved with molecular testing; such is the case of people with weak or partial expression of the D antigen. Since the antibodies of Rh blood group are not spontaneous and are linked to both the possibility of developing hemolytic disease of the newborn and severe transfusion reactions, the administration of anti-D immunoglobulin has been implemented as a risk reduction measure. In developed countries, genotyping methods are used to guide the administration of this vaccine, since, as a product of human origin, its availability is often not the same in all areas where it is required. Understanding the characteristics that distinguish the antigens of this blood group helps us move toward the use of higher-resolution determination methods that allow us to increase blood safety in our patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.